Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Ally Hetero Drugs Beat Ranbaxy, Cipla To Win Oseltamivir Supply Contract From Indian Government

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Hetero Drugs has edged past bigger Indian rivals Ranbaxy and Cipla to bag the government tender floated for supplies of oseltamivir. Hetero received orders to supply nine million capsules of generic versions of Roche's anti-viral brand Tamiflu. The entire contract is believed to be worth $6 to $8 million

You may also be interested in...



Roche In Stand-by Mode To Supply Tamifl& To Indian Government; Others Queue Up Too

MUMBAI - As the Indian government grapples with the threat of influenza H1N1 through countrywide moves to stockpile drugs, protective masks and diagnostic kits, Roche India has said it has been approached for supplies of Tamiflu (oseltamivir) by the Indian health ministry but there are no clear orders issued yet to commence supply of the drugs

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel